| Date | Time | Source | Headline | Symbol | Company |
| 05/15/2024 | 11:45AM | GlobeNewswire Inc. | Transgene’s Combined General Meeting of May 15, 2024 | EU:TNG | Transgene SA |
| 05/15/2024 | 11:45AM | GlobeNewswire Inc. | Assemblée Générale Mixte de Transgene du 15 mai 2024 | EU:TNG | Transgene SA |
| 05/15/2024 | 11:45AM | GlobeNewswire Inc. | Transgene’s Combined General Meeting of May 15, 2024 | EU:TNG | Transgene SA |
| 05/14/2024 | 11:45AM | GlobeNewswire Inc. | Transgene fait le point sur ses activités et sa situation financière au premier trimestre 2024 | EU:TNG | Transgene SA |
| 05/14/2024 | 11:45AM | GlobeNewswire Inc. | Transgene provides business and financial update for Q1 2024 | EU:TNG | Transgene SA |
| 05/14/2024 | 11:45AM | GlobeNewswire Inc. | Transgene provides business and financial update for Q1 2024 | EU:TNG | Transgene SA |
| 04/24/2024 | 11:45AM | GlobeNewswire Inc. | Mise à disposition des documents préparatoires à l'Assemblée générale du 15 mai 2024 | EU:TNG | Transgene SA |
| 04/24/2024 | 11:45AM | GlobeNewswire Inc. | Availability of Preparatory Documents for the Combined General Meeting of May 15, 2024 | EU:TNG | Transgene SA |
| 04/24/2024 | 11:45AM | GlobeNewswire Inc. | Availability of Preparatory Documents for the Combined General Meeting of May 15, 2024 | EU:TNG | Transgene SA |
| 04/11/2024 | 1:05PM | GlobeNewswire Inc. | Document d'enregistrement Universel 2023 | EU:TNG | Transgene SA |
| 04/11/2024 | 11:45AM | GlobeNewswire Inc. | MIse à disposition du document d'enregistrement universel 2023 de Transgene | EU:TNG | Transgene SA |
| 04/11/2024 | 11:45AM | GlobeNewswire Inc. | Availability of Transgene's 2023 Universal Registration Document | EU:TNG | Transgene SA |
| 04/09/2024 | 11:45AM | GlobeNewswire Inc. | Transgene et NEC présentent les premiers signes de bénéfice clinique de leur vaccin individualisé contre le cancer, TG4050, dans les cancers de la tête et du cou à l’AACR 2024 | EU:TNG | Transgene SA |
| 04/09/2024 | 11:45AM | GlobeNewswire Inc. | Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024 | EU:TNG | Transgene SA |
| 04/09/2024 | 11:45AM | GlobeNewswire Inc. | Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024 | EU:TNG | Transgene SA |
| 03/27/2024 | 12:45PM | GlobeNewswire Inc. | Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer | EU:TNG | Transgene SA |
| 03/27/2024 | 12:45PM | GlobeNewswire Inc. | Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025 | EU:TNG | Transgene SA |
| 03/27/2024 | 12:45PM | GlobeNewswire Inc. | Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025 | EU:TNG | Transgene SA |
| 03/27/2024 | 12:45PM | GlobeNewswire Inc. | Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer | EU:TNG | Transgene SA |
| 03/27/2024 | 12:45PM | GlobeNewswire Inc. | Transgene nomme Lucie Larguier en tant que Directrice Financière et Christelle Schwoerer Comme Directrice des Ressources Humaines | EU:TNG | Transgene SA |
| 03/27/2024 | 12:45PM | GlobeNewswire Inc. | Transgene prévoit des avancées significatives sur son portefeuille d’immunothérapies en 2024 et étend sa visibilité financière jusqu’au 4ème trimestre 2025 | EU:TNG | Transgene SA |
| 03/18/2024 | 12:45PM | GlobeNewswire Inc. | Transgene annonce ses prochaines rencontres avec les investisseurs | EU:TNG | Transgene SA |
| 03/18/2024 | 12:45PM | GlobeNewswire Inc. | Transgene Announces Upcoming Investor Meetings | EU:TNG | Transgene SA |
| 03/18/2024 | 12:45PM | GlobeNewswire Inc. | Transgene Announces Upcoming Investor Meetings | EU:TNG | Transgene SA |
| 03/06/2024 | 1:30AM | GlobeNewswire Inc. | Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024 | EU:TNG | Transgene SA |
| 03/06/2024 | 1:30AM | GlobeNewswire Inc. | Transgene présentera de nouvelles données sur son vaccin individualisé TG4050 à l’AACR 2024 | EU:TNG | Transgene SA |
| 03/06/2024 | 1:30AM | GlobeNewswire Inc. | Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024 | EU:TNG | Transgene SA |
| 03/05/2024 | 1:30AM | GlobeNewswire Inc. | Transgene, NEC et BostonGene étendent leur collaboration dans le cadre de l’essai clinique de Phase I/II du vaccin individualisé TG4050 | EU:TNG | Transgene SA |
| 03/05/2024 | 1:30AM | GlobeNewswire Inc. | Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050 | EU:TNG | Transgene SA |
| 03/05/2024 | 1:30AM | GlobeNewswire Inc. | Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050 | EU:TNG | Transgene SA |